Alternative Muscle Growth Strategies: Beyond Myostatin and Androgens

Beyond the Androgen Receptor

Most discussions of muscle growth start with testosterone and other androgens, which act on the androgen receptor in muscle. A second route works by blocking myostatin, the protein that limits how large muscle can get; our myostatin inhibitors overview covers that mechanism. As of October 2026, that route has its first approved drug: the FDA approved apitegromab (Isembyld) in September 2026 for spinal muscular atrophy, not for muscle building.

This page covers a third route lifters ask about: the insulin-like growth factor 1 (IGF-1) system. The compounds in question are two IGF-1 analogs (LR3 and DES) plus mechano growth factor (MGF), usually sold in a PEGylated form. They act downstream of growth hormone without using the androgen receptor. Apart from mecasermin, a prescription form of natural IGF-1 approved for a rare childhood growth disorder, none of these peptides has been studied in a human trial.

How Growth Hormone and IGF-1 Fit Together

Growth hormone (GH) raises blood levels of IGF-1, most of which is made in the liver. GH also prompts IGF-1 production in other tissues, muscle included, where it acts locally. A 2008 review in the British Journal of Pharmacology noted that raising IGF-1 inside muscle reliably causes growth in animal models and cell culture. Yet it found "very little evidence" that pushing systemic GH or IGF-1 above normal levels builds muscle in healthy people. The analogs users buy are taken systemically, by subcutaneous injection, so the weakest part of the evidence is the part that matters most for how they're used.

The IGF-1 Family: LR3 and DES

IGF-1 LR3 (Long R3 IGF-1) is a lab-made IGF-1 with an added N-terminal extension and one amino-acid swap (the "R3"). These changes make it bind poorly to IGF-binding proteins, the carrier proteins that hold most circulating IGF-1 in an inactive state. Weak binding cuts both ways. In a 1999 rat study using implanted wound chambers, LR3 left wound fluid faster than natural IGF-1 (a half-life of about 563 minutes versus 872), and more of it reached the circulation and urine.

Vendor and forum pages often give LR3 a 20-30 hour half-life. A 2026 evidence ledger on Vialog traces that figure to an uncited line in a mouse paper and notes that rat data show LR3 clearing from blood faster than IGF-1. As of October 2026, no human trial of IGF-1 LR3 has been registered or published, and it isn't approved anywhere. Our IGF-1 LR3 profile rates its evidence as preliminary for that reason.

Forum guides often call LR3 the most reliable peptide in this group. The research shows something narrower: strong IGF-1 receptor activity in animals and cell systems, with no test of muscle gain in healthy adults.

IGF-1 DES (des(1-3) IGF-1) is natural IGF-1 missing its first three amino acids. Like LR3, it binds IGF-binding proteins poorly. In a 1997 study in pigs and marmoset monkeys, des(1-3) IGF-1 was the most potent of the tested variants at lowering blood sugar. Users inject it into a just-trained muscle, on the theory that a short-lived, high local concentration will drive growth in that one spot. We found no study testing that idea in people; it rests on forum accounts. A 2017 paper from the Cologne anti-doping laboratory described a plasma test for LR3 and DES, which shows sport labs expect athletes to use them, not that they work.

A Word on Mechano Growth Factor (MGF)

MGF is a splice variant of the IGF-1 gene that muscle produces after mechanical loading. In a 2003 Journal of Physiology study, a single bout of heavy knee-extension exercise raised MGF messenger RNA in the quadriceps of young men but not in men aged 70-82. Geoffrey Goldspink, whose group identified MGF, proposed that it helps start hypertrophy and repair after exercise, partly by activating satellite cells (the muscle stem cells that donate new nuclei to growing fibers).

The injectable products are a synthetic copy of the short tail peptide from that splice variant, usually attached to polyethylene glycol (PEG-MGF) so it lasts longer. In 2014, researchers at two drug companies, Novartis among them, tried to reproduce the effects claimed for the MGF peptide in mouse and human muscle cells and found none, while mature IGF-1 worked as expected. They wrote that their results "call in to question" whether the MGF peptide has a physiological role.

The idea that injected MGF causes hyperplasia (new muscle fibers) in people has no direct support. Some users credit PEG-MGF with helping a lagging muscle group while others notice nothing. As of October 2026, we found no published human trial of MGF or PEG-MGF.

Reported Use vs. Tested Doses

The only IGF-1 product with human dosing data is mecasermin (Increlex), a recombinant copy of natural IGF-1. Its FDA label covers growth failure in children aged 2 and older with severe primary IGF-1 deficiency, or with GH gene deletion and neutralizing antibodies to GH. The labeled starting dose is 0.04-0.08 mg/kg twice daily by subcutaneous injection, increased if tolerated to at most 0.12 mg/kg twice daily. Those doses were set for children with a deficiency, not for adults with normal IGF-1 levels.

For the analogs, all dosing information comes from vendors and users:

User accounts commonly describe injecting LR3 after training and eating carbohydrates soon afterward (often 30-50 g within about 30 minutes) to head off low blood sugar. A common community stack pairs PEG-MGF around training with LR3 later the same day or the next morning. None of these timing schemes has been tested, and neither the post-workout "receptor sensitivity" rationale nor the downregulation said to justify short cycles has been measured for these analogs.

The mecasermin label offers a contrast: it tells patients to avoid high-risk activities, exercise included, for 2-3 hours after a dose, especially early in treatment. Many user protocols place the injection right around a workout.

Hypoglycemia and Nutrient Partitioning

IGF-1 lowers blood sugar in a way similar to insulin. The mecasermin label lists severe hypoglycemia, including hypoglycemic seizures, among its warnings. It says the drug should be given within 20 minutes before or after a meal or snack and never when the meal is skipped.

The analogs may carry more of this risk, not less. In the 1997 pig and marmoset study, IGF-1 variants that bind poorly to IGF-binding proteins (LR3 and DES among them) were 2-3 times more potent than IGF-1 at lowering blood glucose to its lowest point. Over four hours they produced about 4-8 times more cumulative hypoglycemia, even though they cleared from the blood faster. User reports point the same way. Shakiness and sweating after injecting, sometimes with tunnel vision, are the acute problems described most often with LR3.

The label also warns of raised pressure inside the skull and of enlarged tonsils and adenoids in treated children. Postmarketing reports of cancer led to a contraindication in children with active or past malignancy. How these translate to adults using unapproved analogs is unknown, but they are the only human safety record for this receptor.

Users also describe LR3 as steering carbohydrates into muscle rather than fat during a calorie surplus (nutrient partitioning). In the pig study, LR3 lowered plasma amino acids more than IGF-1 at the higher dose, which fits with uptake into tissue, but no study has measured body composition changes from LR3 in people.

Sport and Legal Status

As of October 2026, WADA's 2026 Prohibited List names "insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues" and "mechano growth factors (MGFs)" under S2.3 (growth factors and growth factor modulators). Both entries are prohibited at all times, which covers every compound on this page. Myostatin-pathway drugs sit in a separate class, S4.3. In the US, mecasermin is a prescription medicine for a narrow pediatric indication. The other compounds here are sold as research chemicals and aren't approved for human use.

What We Still Don't Know

• Whether any IGF-1 analog adds muscle in healthy adults. No trial has tested it, and the 2008 review found little support even for natural IGF-1 given systemically.
• How long LR3 or DES lasts in the human body. The widely quoted half-life figures don't come from measurements in people.
• Whether the synthetic MGF peptide does anything in muscle, given the 2014 replication failure.
• Long-term safety in adults, including effects on existing tumors.

For how these peptides compare with anabolic steroids and myostatin-pathway drugs on the human data that exist, see our comparison of myostatin inhibitors and traditional anabolics.